has been involved in managing and financing US life sciences companies
since 1981. He began his career at Genentech (NYSE: DNA), where he spearheaded
its business development activities for the first several years. He
was then Project Manager for the launch of Protropin® (human growth
hormone), the first product marketed by Genentech. In 1987, he became
head of corporate finance in the investment banking division of Paribas
Capital Markets LTD in Tokyo, where he helped finance Japanese government
agencies, municipalities and corporations in the Euro market. He also
helped numerous life sciences companies raise capital. He then became
Senior Vice President and CFO of Isis Pharmaceuticals (NASDAQ: ISIS),
which went public during his tenure there. In 1992, he was recruited
to be the original business executive at Tularik (acquired by Amgen
in 2004), where at various times he was CFO and VP-Business Development
until its public offering in 1999. He served on the board of LeukoSite
until its merger with Millennium Pharmaceuticals (NASDAQ: MLNM) in 1999.
He received an undergraduate degree from Keio University in Tokyo, a
medical degree from Keio University School of Medicine, and an M.B.A.
from Stanford Business School. He joined Skyline in 1999. He committed
to golf several years ago after an unfortunate heading incident at a
team reunion for his junior All-Star soccer team.